The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on May 30, 2023. The analyst firm set a price target for $4.00 expecting ADXS to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on May 30, 2023 so you should expect the next rating to be made available sometime around May 30, 2024.

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.94, which is within the analyst’s predicted range.